<i>Mycobacterium tuberculosis</i>infection boosts B cell responses to unrelated pathogens

Kimuda, Simon G.; Andia-Biraro, Irene; Sebina, Ismail; Egesa, Moses; Nalwoga, Angela; Smith, Steven G.; Bagaya, Bernard S.; Levin, Jonathan; Elliott, Alison M.; Raynes, John G.; Cose, Stephen

doi:10.1101/680058

Cited by 2 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study demonstrates the significant enhancement of antibody titres against heterologous pathogens following low-dose M.tb challenge in NHPs. This is consistent with the findings of Kimuda et al, who observed higher heterologous antibody responses in patients with pulmonary TB disease compared with uninfected controls in Uganda, and provides validation of this effect in a more controlled system that enables the direct comparison of matched preand post-infection samples (40). Once the human data were adjusted for potential confounders, active TB was associated with higher levels of anti-RSV and anti-measles antibodies compared to the uninfected individuals (40).…”

Section: Discussionsupporting

confidence: 88%

“…The current study aimed to determine whether infection with M.tb, or vaccination with BCG or MTBVAC, influences antibody responses to a range of unrelated pathogens. Kimuda et al have previously shown that active pulmonary TB patients in Uganda had higher antibody responses to respiratory syncytial virus (RSV) and measles virus (MV) compared with uninfected controls, while BCG vaccination in uninfected UK adults did not alter levels of antibodies against heterologous pathogens (40). There were some limitations to this study including inability to measure matched pre-and post-M.tb infection responses in the same individuals, and the unknown time after infection that samples were collected.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Peralta Alvarez,

Jones,

Redondo Azema

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionMycobacteria are known to exert a range of heterologous effects on the immune system. The mycobacteria-based Freund’s Complete Adjuvant is a potent non-specific stimulator of the immune response used in immunization protocols promoting antibody production, and Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccination has been linked with decreased morbidity and mortality beyond the specific protection it provides against tuberculosis (TB) in some populations and age groups. The role of heterologous antibodies in this phenomenon, if any, remains unclear and under-studied.MethodsWe set out to evaluate antibody responses to a range of unrelated pathogens following infection with Mycobacterium tuberculosis (M.tb) and vaccination with BCG or a candidate TB vaccine, MTBVAC, in non-human primates.ResultsWe demonstrate a significant increase in the titer of antibodies against SARS-CoV-2, cytomegalovirus, Epstein-Barr virus, tetanus toxoid, and respiratory syncytial virus antigens following low-dose aerosol infection with M.tb. The magnitude of some of these responses correlated with TB disease severity. However, vaccination with BCG administered by the intradermal, intravenous or aerosol routes, or intradermal delivery of MTBVAC, did not increase antibody responses against unrelated pathogens.DiscussionOur findings suggest that it is unlikely that heterologous antibodies contribute to the non-specific effects of these vaccines. The apparent dysregulation of B cell responses associated with TB disease warrants further investigation, with potential implications for risk of B cell cancers and novel therapeutic strategies.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Peralta Alvarez,

Jones,

Redondo Azema

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The optical, (piezo)electrical, or (micro)mechanical transducers are among the promising methods for recognizing ligand-receptor interaction signals in label-free biosensors used for the diagnosis of various infectious diseases. These biosensing methods are enhanced by surface plasmon resonance (SPR) [78], surface Raman spectrometry (SERS) [36,38,39], quartz crystal microbalance [86], and microcantilever sensors [78,87,88].…”

Section: Label-free Biosensorsmentioning

confidence: 99%

“…The biosensors with optical transducers, considered as the main tools for signal perception, are one of the most powerful detection and analysis tools widely used in biomedical research and practical medicine [8,9,72,88,89]. These transducers are based on measuring changes in optical properties in the presence of the analyte, such as absorption, reflectivity, radiation, or interferometric pattern, which can be detected by a photodetector.…”

Section: Label-free Biosensorsmentioning

confidence: 99%

“…This is due to the high sensitivity and versatility of this type of sensors, which also allow real-time detection and direct measurement of the kinetics of molecular ligand-receptor interaction [71,80]. For example, in recent years, a number of researchers [61,62,78,88,96] have proposed SPR-based biosensors for detecting and monitoring urinal M. tuberculosis biomolecules and non-tuberculosis CFP10 and MPT64 mycobacteria, which, among numerous mycobacteria antigens, interact most strongly with related anti-CFP10 and anti-MPT64 antibodies on the immunosensor matrix.…”

Section: Recognizing Bioreceptormentioning

confidence: 99%

See 1 more Smart Citation

Biosensor Technologies in Medicine: from Detection of Biochemical Markers to Research into Molecular Targets (Review)

Andryukov¹,

Lyapun²,

Матосова³

et al. 2020

Sovrem Tehnol Med

View full text Add to dashboard Cite

Infections are a major cause of premature death. Fast and accurate laboratory diagnostics of infectious diseases is a key condition for the timely initiation and success of treatment. Potentially, it can reduce morbidity, as well as prevent the outbreak and spread of dangerous epidemics. The traditional methods of laboratory diagnostics of infectious diseases are quite time- and labour-consuming, require expensive equipment and trained personnel, which is crucial within limited resources. The fast biosensor-based methods that combine the diagnostic capabilities of biomedicine with modern technological advances in microelectronics, optoelectronics, and nanotechnology make an alternative. The modern achievements in the development of label-free biosensors make them promising diagnostic tools that combine rapid detection of specific molecular markers, simplicity, ease-of-use, efficiency, accuracy, and cost-effectiveness with the tendency to the development of portable platforms. These qualities exceed the generally accepted standards of microbiological and immunological diagnostics and open up broad prospects for using these analytical systems in clinical practice directly at the site of medical care provision (point-of-care, POC concept). A wide variety of modern biosensor designs are based on the use of diverse formats of analytical and technological strategies, identification of various regulatory and functional molecular markers associated with infectious pathogens. The solution to the existing problems in biosensing will open up great prospects for these rapidly developing diagnostic biotechnologies.

show abstract

Mycobacterium tuberculosisinfection boosts B cell responses to unrelated pathogens

Cited by 2 publications

References 33 publications

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Biosensor Technologies in Medicine: from Detection of Biochemical Markers to Research into Molecular Targets (Review)

Contact Info

Product

Resources

About